FindTrial
Sign In

Several methods resolve the interference of anti-CD38 monoclonal antibody on blood compatibility tests

Methodological research on overcoming the interference of CD38 monoclonal antibody on blood compatibility tests

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040761
Enrollment
Unknown
Registered
2020-12-09
Start date
2021-01-08
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Case series:Treated with 2-ME or polybrene

Sponsors

Ruijin Hospital, School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with multiple myeloma need blood transfusion.

Exclusion criteria

Exclusion criteria: Patients with multiple myeloma do not need blood transfusion.

Design outcomes

Primary

MeasureTime frame
Cross matching;—

Countries

China

Contacts

Public ContactXiaohong Cai

Ruijin Hospital, School of Medicine, Shanghai Jiaotong University

cxh8407@shsmu.edu.cn+86 13564306596

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026